FG-4592: Clinical Trials

14 trials of FG-4592, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 2 active not recruiting, 1 not yet recruiting, 1 terminated. 14 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 9, Active not recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 21Completed 1

Follow FG-4592: new trials by email Literature Review of FG-4592 trials Research Report on FG-4592

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
Roxadustat, Placebo - Myelodysplastic Syndromes
Phase 3Not yet recruitingKyntra Bio2012027-04-012026-07-23
Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.
Roxadustat - Perioperative Anemia
Phase 3Active not recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1582024-11-102025-01-13
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Roxadustat - Chronic Kidney Disease, Renal Anemia
Phase 3Active not recruitingAstellas Pharma Global Development, Inc.982024-01-162026-10-13
Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
Roxadustat - Anemia Associated With Chronic Kidney Disease
Phase 3WithdrawnKyntra Bio2022-05-232022-07-05
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
SEPO®, Roxadustat - Chemotherapy Induced Anemia
Phase 3CompletedKyntra Bio1592022-03-162023-06-06
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
FG-4592, Placebo - Anemia, Myelodysplastic Syndrome
Phase 2 / Phase 3CompletedKyntra Bio432018-06-062023-05-03
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
Roxadustat, Placebo - Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Phase 3TerminatedKyntra Bio1842018-01-292024-08-01
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
FG-4592, Epoetin Alfa - Anemia
Phase 3CompletedKyntra Bio3052015-12-012017-08-24
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
FG-4592, Placebo - Anemia
Phase 3CompletedKyntra Bio1542015-12-012017-08-24
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Epoetin Alfa, Roxadustat - CKD Anemia in Stable Dialysis Patients
Phase 3CompletedKyntra Bio7412015-01-152021-10-29
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Roxadustat, Epoetin alfa, Darbepoetin alfa - Anemia, End Stage Renal Disease (ESRD)
Phase 3CompletedAstellas Pharma Europe B.V.8382014-11-212024-11-27
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
Roxadustat, Epoetin Alfa - Anemia in Incident Dialysis Patients
Phase 3CompletedKyntra Bio10432014-02-112021-10-01
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Roxadustat, Placebo - Anemia in Chronic Kidney Disease in Non-dialysis Patients
Phase 3CompletedAstellas Pharma Europe B.V.5942013-09-032024-11-14
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
Roxadustat, Placebo - CKD Anemia
Phase 3CompletedKyntra Bio9222012-11-052021-10-01

Conditions studied

Anemia (13)  ·  Renal Insufficiency, Chronic (9)  ·  Kidney Failure, Chronic (5)  ·  Myelodysplastic Syndromes (3)

Sponsors

Kyntra Bio (10)  ·  Astellas Pharma Europe B.V. (2)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Countries

China (5)  ·  Poland (5)  ·  United States (5)  ·  Belgium (4)  ·  Italy (4)  ·  Romania (4)  ·  Russia (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Bulgaria (3)  ·  Colombia (3)  ·  Germany (3)  ·  South Korea (3)  ·  Turkey (Türkiye) (3)  ·  Argentina (2)

Top investigators

Charles Bradley, PhD (1)  ·  Mark Eisner, MD, MPH (1)  ·  Meraf Eyassu (1)  ·  Min Yan, MD, PhD (1)

Results publications

PMID 36005278, PMID 38363466, PMID 34362786, PMID 36749544, PMID 31340089, PMID 31340116, PMID 33732977, PMID 34724251, PMID 36710399, PMID 39353163